Impact Factor
3.66
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.31
1,448 total citations
h5-index
40
h5 depth signal
Cited share
73.0%
332 of 455
Total citations
1,448
Citation footprint
Metric signal
3.02
External metric anchor
Self-citation
1.2%
18 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,172
China
404
United Kingdom
213
South Korea
133
France
105
Citing Fields of Research
Pharmacology & Toxicology
360
Cardiology
346
Diabetes
308
Medical Ethics
307
Antibiotic & Antibacterial Agents
171
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
8,655
Articles tracked across the journal lifetime
Indexed publication set
455
332 cited publications
Last 12 months
250
20.8 publications/month
Open access share
31.2%
78 OA publications in the last year
Leading citing country
United States
1,172 citing publications
Leading citing field
Pharmacology & Toxicology
360 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v3n1, 1980-
v3n1, 1980-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Substance Abuse
Pharmacology & Toxicology
Diabetes
Anesthetic & Pain Medicine
Hematology
Medical Ethics
Broad Categories
Drug Therapy
Therapeutics
Medical Ethics
Diabetes
Cardiology
Substance Abuse
Musculoskeletal Disorders
Hematology
MeSH Descriptors
Drug Therapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.clinthera.2026.10.001
Open DOI
Evaluation of Inpatient Epoetin Alfa Dosing in Patients With Anemia of Chronic Kidney Disease: A Retrospective Cohort Study
02
DOI 10.1016/j.clinthera.2026.09.014
Open DOI
Time-matched Secondary Fracture Prevention in Older Adults: A Narrative Review of Imminent Risk, Time-to-Benefit, and Treatment Sequencing
03
DOI 10.1016/j.clinthera.2026.09.012
Open DOI
First Oral Carbapenem Comes to the United States, a Mixed Blessing
04
DOI 10.1016/j.clinthera.2026.09.009
Open DOI
Relapse After Dupilumab Discontinuation in Pediatric Moderate-to-Severe Atopic Dermatitis: A Single-Center Retrospective Study From China
05
DOI 10.1016/j.clinthera.2026.09.011
Open DOI
The Promises and Pitfalls of Medical Device Oversight
06
DOI 10.1016/j.clinthera.2026.09.004
Open DOI
Remimazolam Versus Propofol During Hysteroscopy: A Systematic Review And Meta-Analysis of Nine Randomized Controlled Trials
07
08
DOI 10.1016/j.clinthera.2026.09.001
Open DOI
UTEBZI (tebipenem pivoxil)
09
DOI 10.1016/j.clinthera.2026.09.005
Open DOI
Safety Challenges and Emerging Solutions in Regenerative Medicine: Tissue Engineering, Cell Therapy, and Gene Therapy
10
DOI 10.1016/j.clinthera.2026.09.002
Open DOI
Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity
Bibliographical & Catalog Notes
Supplements accompany some vols.
Also available online.
Vol. 11, no. 1 (1989)19900917 Notice not published Printed on acid-free paper